Angiotensin Peptides and Cancer

Handbook of Biologically Active Peptides

Volumn , Issue , 2006, Pages 459-465

  Ann, Tallant ^a   Menon, Jyotsana ^a   Soto Pantoja, David R ^a   Gallagher, Patricia E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73149090285     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369442-3/50069-6     Document Type: Chapter

References (49)

1. Arrieta O., Guevara P., Escobar E., Garcia-navarrete R., Pineda B., Sotelo J. Blockade of angiotensin II type 1 receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 2005, 1247-1255.
2. 1 receptors. Cancer Lett 1994, 76:19-24.
3. Chen L., Re R.N., Prakash O., Mondal D. Angiotensinconverting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 1991, 196:280-283.
4. De Paepe B., Verstraeten V.L., De Potter C.R., Vakaet L.A., Bullock G.R. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 2001 Sep, 116(3):247-254.
5. Egami K., Murohara T., Shimada T., Sasaki K., Shintani S., Sugaya T., Ishii M., Akagi T., Ikeda H., Matsuishi T., Imaizumi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003, 112:67-75.
6. Ferrario, C. M.; Averill, D. B.; Brosnihan, K. B.; Chappell, M. C.; Diz, D. I.; Gallagher, P. E.; Tallant, E. A. Angiotensin-(1-7). Its contribution to arterial pressure control mechanisms. In: Unger, T.; Scholkens, B., Eds. Handbook of Experimental Pharmacology. Heidelberg, Germany: 2004, 478-518.
7. Ferrario C.M., Chappell M.C., Tallant E.A., Brosnihan K.B., Diz D.I. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997, 30(part 2):535-541.
8. Freeman E.J., Chisolm G.M., Ferrario C.M., Tallant E.A. Angiotenin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996, 28:104-108.
9. Frcitas-Silva M., Pereira D., Coelho C., Bicho M., Lopes C., Medeiros R. Angiotensin I-converting enzyme gene insertion/deletion polymorphism and endometrial human cancer in normotensive and hypertensive women. Cancer Genet Cytogenet 2004, 155:42-46.
10. Friis S., Sorensen H.T., Mellemkuacr L., McLaughlin J.K., Nielsen G.L., Blot W.J., Olsen J.H. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001, 92:2462-2470.
11. Fujita M., Hayashi I., Yamashina S., Fukamizu A., Itoman M., Majima M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005 Feb, 26(2):271-279.
12. Fujita M., Hayashi I., Yamashina S., Itoman M., Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002, 294:441-447.
13. Gallagher P.E., Tallant E.A. Inhibition of lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 2004, 25:2045-2052.
14. Greco S., Elia M.G., Muscella A., Storelli C., Marsigliante S. AT1 angiotensin II receptor mediates intracellular calcium mobilization in normal and cancerous breast cells in primary culture. Cell Calcium 2002, 32:1-10.
15. Greco S., Muscella A., Elia M.G., Salvatore P., Storelli C., Mazzotta A., Manca C., Marsigliante S. Ang II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor in breast cancer cells. J Cell Physiol 2003, 106:370-377.
16. Haiman C.A., Henderson S.O., Bretsky P., Kolonel L.N., Henderson B.E. Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. Cancer Res 2003, 63:6984-6987.
17. Hii S.I., Nicol D.L., Gotley D.C., Thompson L.C., Green M.K., Jonsson J.R. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998, 77:880-883.
18. Jaiswal N., Tallant E.A., Diz D.I., Khosla M.C., Ferrario C.M. Subtype 2 angiotensin receptors mediate prostaglandin synthesis in human astrocytes. Hypertension 1991, 17:1115-1120.
19. Jick H., Jick S., Derby L.E., Vasilakis C., Myers M.W., Meier C.R. Calcium-channel blockers and risk of cancer. Cancer 1997, 349:525-528.
20. Koh W.-P., Yuan J.-M., Sun C.-L., Van Den Berg D., Seow A., Lee H.-P., Yu M.C. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer. Risk among Chinese women in Singapore. Cancer Res 2003, 63:573-578.
21. Koh W.-P., Yuan J.-M., Van Den Berg D., Lee H.-P., Yu M.C. Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risks among Chinese women in Singapore. Carcinogenesis 2005, 26:459-464.
22. Lever A.F., Hole D.J., Gillis C.R., McCallum I.R.M.G.T., MacKinnon P.L., Meredith P.A., Murray L.S., Reid J.L., Robertson M.J. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. The Lancet 1998, 352:179-184.
23. Li X., Zhang H., Soledad-Conrad V., Zhuang J., Uhal B.D. Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol Cell Physiol 2003, 284:L501-L507.
24. Lindberg H., Nielsen D., Jensen B.V., Eriksen J., Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment?. Acta Oncol 2004, 43(2):142-152.
25. Machado R.D., Santos R.A., Andrade S.P. Opposing actions of angiotensins on angiogenesis. Life Sci 2000, 66(1):67-76.
26. Machado R.D.P., Santos R.A.S., Andrade S.P. Mechanisms of angiotensin-(1-7)-induced inhibition of angiogenesis. Am J Physiol Regulatory Integrative Comp Physiol 2001, 280:994-1000.
27. Meier C.R., Derby L.E., Jick S.S., Jick H. Angiotensinconverting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000 Feb, 160(3):349-353.
28. Michels K.B., Rosner B.A., Walker A.M., Stampfer M.J., Manson J.E., Colditz G.A., Hennekens C.H., Willett W.C. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the murses' health study. Cancer 1998 Nov, 83(9):2003-2007.
29. Miyajima A., Kosaka T., Asano T., Asano K., Seta K., Kawai T., Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogensis. Cancer Res 2002, 62:4176-4179.
30. Muscella A., Greco S., Elia M.G., Storelli C., Marsigliante S. PKC-z is required for angiotensin II-induced activation of ERK and synthesis of C-FOS in MCF-7 cells. J Cell Physiol 2003, 197:61-68.
31. Nadal J.A., Scicli G.M., Carbini L.A., Scicli G. Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGFβ and PDGF-BB. Am J Physiol Heart Circ Physiol 2002, 282:H738-H748.
32. Pahor M., Guralnik J.M., Salive M.E., Corti M.-C., Carbonin P., Havlik R.J. Do calcium channel blockers increase the risk of cancer?. Am J Hypertens 1996, 9:695-699.
33. 1 mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol 2002, 282:L713-L718.
34. Reddy M.K., Baskaran K., Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 1995 Dec, 210(3):221-226.
35. Rivera E., Arrieta O., Guevara P., Duarte-Rojo A., Sotelo J. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer 2001 Nov, 85(9):1396-1399.
36. Santos R.A.S., Simoes E., Silva A.C., Maric C., Silva D.M.R., Machado R.D., DuBuhr I., Heringer-Walther S., Pinheiro S.V., Lopes M.T., Bader M., Mendes E.P., Lemos V.S., Campagnole-Santos M.J., Schultheiss H.-P., Speth R., Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor mas. Proc Natl Acad Sci USA 2003, 100:8258-8263.
37. Small W., Molteni A., Kim Y.T., Taylor J.M., Chen Z., Ward W.F. Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat 1997 Aug, 44(3):217-224.
38. Soto-Pantoja D., Gallagher P.E., Tallant E.A. Inhibition of human breast cancer cell growth by angiotensin-(1-7). Proceedings of the American Association for Cancer Research 2004, 45.
39. Strawn W.B., Ferrario C.M., Tallant E.A. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999, 33(part II):207-211.
40. Suganuma T., Ino K., Shibata K., Kajiyama H., Nagasaka T., Mizutani S., Kikkawa F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005, 11:2686-2694.
41. Tallant E.A., Diz D.I., Ferrario C.M. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 1999, 34(part 2):950-957.
42. Tallant E.A., Ferrario C.M. Biology of angiotensin II receptor inhibition with a focus on losartan: a new drug for the treatment of hypertension. Exp Opin Invest Drugs 1996, 5:1201-1214.
43. Tallant E.A., Ferrario C.M., Gallagher P.E. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005, 289:H1560-H1566.
44. Tallant E.A., Lu X., Weiss R.B., Chappell M.C., Ferrario C.M. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension 1997, 29(part 2):388-393.
45. Uemura H., Ishiguro H., Nakaigawa N., Nagashima Y., Miyoshi Y., Fujinami R., Sakaguchi A., Kubota Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Molecular Cancer Therapeutics 2003, 2:1139-1147.
46. Volpert O.V., Ward W.F., Lingen M.W., Chesler L., Solt D.B., Johnson M.D., Molteni A., Polverini P.J., Bouck N.P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996, 98:671-679.
47. Wang R., Zagariya A., Ang E., Ibarra-Sunga O., Uhal B.D. Fas-induced apoptosis of alveolar epithelial cells requires ANG II generation and receptor internalization. Am J Physiol Lung Cell Mol Physiol 1999, 277:L1245-L1250.
48. Wang R., Zagariya A., Ibarra-Sunga O., Gidea C., Ang E., Deshmukh S., Chaudhary G., Baraboutis J., Filippatos G., Uhal B.D. Angiotensin II induces apoptosis in human and rat alveolar epithelial cells. Am J Physiol 1999 May, 276(5):L885-L889. Pt I.
49. Yoshiji H., Kuriyama S., Kawata M., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., Tsujinoue H., Fukui H. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Research 2001, 7:1073-1078.